Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $63.3 million SEC-registered offering of 6,325,000 shares of common stock of OncoMed Pharmaceuticals, Inc., which includes the full exercise of the underwriters’ option to purchase additional securities. The common stock is listed on the NASDAQ Global Select Market under the symbol “OMED.”
Based in Redwood City, California, OncoMed Pharmaceuticals, Inc. is a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.
The Davis Polk corporate team included partners Sophia Hudson and Bruce K. Dallas and associates Pedro J. Bermeo, Hillary A. Coleman and Amy Tu. The tax team included partners Michael Farber and Rachel D. Kleinberg and associate Anne L. Doherty. The intellectual property and technology team included associates Michelle Ontiveros Gross and Jason J. Bang. Members of the Davis Polk team are based in the New York and Northern California offices.